The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: Implications for prognosis and treatment

Reviews in Cardiovascular Medicine

Volumn 6, Issue 1, 2005, Pages 1-10

  McCullough, Peter A ^a   Lepor, Norman E ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; Diabetes; Erythropoietin

Indexed keywords

ABCIXIMAB; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ESTROGEN; ETANERCEPT; FUROSEMIDE; GESTAGEN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; REACTIVE OXYGEN METABOLITE;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; EXERCISE TEST; FUNCTIONAL ASSESSMENT; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODILUTION; HEMOGLOBIN SYNTHESIS; HORMONE SUBSTITUTION; HUMAN; KIDNEY FAILURE; MALNUTRITION; MORBIDITY; MORTALITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURVIVAL;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DIABETES COMPLICATIONS; ERYTHROPOIETIN; HUMANS; KIDNEY FAILURE; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 16244373737     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. McCullough PA. Cardiorenal risk: an important clinical intersection. Rev Cardiovasc Med. 2002;3:71-76.
2. McCullough PA. Scope of cardiovascular complications in patients with kidney disease. Ethn Dis. 2002;12:S3-44-8.
3. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725-728.
4. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl. 2003;(87):S32-S39.
5. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291: 844-850.
6. McCullough PA. Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. Adv Chronic Kidney Dis. 2004;11:184-191.
7. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225-232.
8. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
9. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-1592.
10. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44: 1593-1600.
11. National Kidney Foundation. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York: National Kidney Foundation; 1997.
12. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354.
13. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13: 504-510.
14. McClellan W, Tran L-L, the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: final results from the PAERI study [abstract SA-P0955]. Program and abstracts of Renal Week 2002: American Society of Nephrology 35th Annual Meeting; November 1-4, 2002; Philadelphia, PA.
15. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59:725-731.
16. Herzog CA, Muster HA, Collins AJ, et al. J Card Fail. 2004;10(6):467-472.
17. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-362.
18. Bolton WK, Kliger AS. Chronic renal insufficiency: current understandings and their implications. Am J Kidney Dis. 2000;36:S4-S12.
19. Jones RL, Peterson CM. Hematologic alterations in diabetes mellitus. Am J Med. 1981; 70:339-352.
20. Yun YS, Lee HC, Yoo NC, et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract. 1999; 46:223-229.
21. Rarick MU, Espina BM, Colley DT, et al. Treatment of a unique anemia in patients with IDDM with epoetin alfa. Diabetes Care. 1998;21:423-426.
22. Winkler AS, Marsden J, Chaudhuri KR, et al. Erythropoietin depletion and anaemia in diabetes mellitus. Diabetes Med. 1999;16: 813-819.
23. Bosman DR, Winkler AS, Marsden JT, et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495-499.
24. Kojima K, Totsuka Y. Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Diabetes Res Clin Pract. 1995;27:229-233.
25. Ricerca BM, Todaro L, Caputo S, et al. Blunted erythropoietin response to anemia in type 1 diabetic patients. Diabetes Care 1999;22:647.
26. Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. Nephrol. 1998; 11:83-86.
27. Cotroneo P, Ricerca MB, Todaro L, et al. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab Res Rev. 2000;16:172-176.
28. Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron. 1997;75:426-430.
29. Schuster SJ, Koury ST, Bohrer M, et al. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol. 1992;81:153-159.
30. Andersson B, Marin P, Lissner L, et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care. 1994; 17: 405-411.
31. Fried W, Gurney CW. The erythropoietic-stimulating effects of androgens. Ann N Y Acad Sci. 1968;149:356-365.
32. Hussein SJ, Jain R, Shlipak MG, et al. Chronic heart failure is not an independent cause of anemia. J Card Fail. 2003;9:19.
33. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
34. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-966.
35. Al-Ahmed A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2002;39:955-962.
36. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
37. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110: 149-154.
38. Marathias KP, Agroyannis B, Mavromoustakos T, et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem. 2004;4:483-486.
39. Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol. 1994;73:908-910.
40. King D, Smith ML, Chapman TJ, et al. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25:144-149.
41. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85:51-66.
42. Doehner W, Anker SD. Cardiac cachexia in early literature: a review of research prior to medline. Int J Cardiol. 2002;85:7-14.
43. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107: 226-229.
44. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure. Radical thoughts. Chest. 2001;120:2035-2046.
45. Siems WG, Sommerburg O, Grune T. Erythrocyte free radical and energy metabolism. Clin Nephrol. 2000;53(suppl 1):S9-S17.
46. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53(suppl 1):S18-S22.
47. Sommerburg O, Grune T, Hampl H, et al. Does treatment of renal anemia with recombinant erythrotopoietin influence oxidative stress in hemodialysis patients? Clin Nephrol. 2000;53(suppl 1):S23-S29.
48. Ludat K, Sommerburg O, Grune T, et al. Oxidation parameters in complete Correction of renal anemia. Clin Nephrol. 2000;53 (suppl 1):S30-S35.
49. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352-1356.
50. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;39:957-962.
51. Silverberg DS, et al. Clin Nephrol. 2003;60 (suppl 1):S93-S102.
52. Silverberg DS, et al. Int J Cardiol. 2004. In press.
53. Amin MG, Tighiouart H, Weiner DE, et al. Hematocrit and left ventricular mass: The Framingham Heart Study. J Am Coll Cardiol. 2004;43:1276-1282.
54. Hampl H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Clin Nephrol. 2002;58(suppl 1): S73-S96.
55. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium derived nitric oxide production by the protein kinase Akt. Nature. 1999 Jun 10;399(6736):597-601. Erratum in: Nature 1999 Aug 19;400(6746): 792.
56. Kang, JQ Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979.
57. Kang, JQ Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979.
58. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346.
59. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Circulation. 2004;109:2487-2491.
60. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
61. Silverberg DS, Blum M, Agbaria Z, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001;55:212-219.
62. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-1780.
63. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
64. Arant CB, Wessel TR, Olson, MS et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. J Am Coll Cardiol. 2004;43:2009-2014.
65. Reinecke E, Trey T, Wellman J, et al. Hemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J. 2003;24:2142-2150.
66. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
67. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103: 368-375.
68. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
69. Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol. 2004;44: 547-553.
70. Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230-1236.
71. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562.